SPOTLIGHT -
No Racial Difference in Recurrence-Free Survival in HR+, HER2- Breast Cancer
Race demonstrated differences in overall survival outcomes, but not for three-year recurrence-free survival in patients with HR-positive, HER2-negative breast cancer, according to data.
Calquence Had Fewer Heart Complications Than Imbruvica in CLL Treatment
Fewer patients with chronic lymphocytic leukemia experienced cardiac toxicities with Calquence than those treated with Imbruvica, research showed.
